Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ALKERMES       

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Alkermes Plc : Morning Research on Valeant Pharma Intl., Hospira, Delcath Systems, and Alkermes

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/11/2013 | 01:05pm CEST

LONDON, March 11, 2013 /PRNewswire/ --

The two biggest trends in the healthcare industry in the last one year have been the Affordable Care Act (ACA) and the expiration of patents on several blockbuster drugs. These trends are expected to have a major impact on drug delivery companies such as Valeant Pharmaceuticals International Inc. (NYSE: VRX), Hospira Inc. (NYSE: HSP), Delcath Systems Inc. (NASDAQ: DCTH) and Alkermes Plc (NASDAQ: ALKS). While supporters of ACA state that the increase in the number of insured individuals as a result of the reform will ultimately benefit healthcare companies, critics on the other hand are saying that rising costs due to ACA will hurt innovation as companies will have to scale back research and development expenses. On Friday, healthcare stocks ended mostly higher, tracking gains in the broad market. StockCall has posted free technical research reports on VRX, HSP, DCTH, and ALKS and these can be accessed by signing up at

http://www.stockcall.com/analysis

Shares of Valeant Pharmaceuticals International Inc. rose sharply in Friday's trading session. The stock closed 1.35% higher at $70.78. It reached a 52-week high of $70.85 in Friday's session. Valeant shares have had an excellent run in 2013. Year-to-date, the stock has gained more than 18%. The stock recently broke through $68 resistance level, which is a strong bullish signal. The bullish trend is further confirmed by the recent volume activity and the MACD chart. Download the free report on VRX upon registration at

http://www.StockCall.com/VRX031113.pdf

Shares of Hospira Inc. also rose sharply in Friday's trading session. The stock closed 1.52% higher at $30.11, extending its gains in the last three trading sessions to over 3%. Despite the recent gains, Hospira Inc. shares are still down more than 3.60% for the year. The losses have been mainly due to a sharp decline last month. The company's shares are currently trading well below their 50-day and 200-day moving averages. However, the stock's MACD chart suggests that the bearish trend has come to an end. The stock's MACD recently crossed above the signal line. HSP technical report can be accessed for free by signing up at

http://www.StockCall.com/HSP031113.pdf

Shares of Delcath Systems Inc. rallied in Friday's trading session. The stock closed 4.26% higher at $1.96, extending its gains in the last three trading sessions to nearly 16%. Delcath shares have had an excellent run in 2013, gaining nearly 60%. The stock recently broke through $1.70 resistance level, which is a strong bullish signal. The positive trend is further confirmed by recent volume activity. The stock has finished higher in 9 of the previous 10 trading sessions. The stock's MACD is also trading above the signal line and zero-line, further confirming the upbeat trend. The free report on DCTH can be downloaded by signing up now at

http://www.StockCall.com/DCTH031113.pdf

Shares of Alkermes Plc also edged higher in Friday's trading session. The stock closed 1.46% higher at $22.87. Year-to-date, the company's shares have now gained nearly 23.50%. The stock has just broken through $22.50 resistance level. It currently has strong support at around $22. The MACD chart for Alkermes is giving strong bullish signals. The stock's MACD is trading well above the signal line and the zero-line. The stock is also trading above its 50-day and 200-day moving averages. Free report on ALKS can be accessed by registering at

http://www.StockCall.com/ALKS031113.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com

SOURCE StockCall.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALKERMES
09/19 ALKERMES : Announces Webcast of Analyst and Investor Event on September 26, 2016
09/12 ALKERMES : Launches Competitive Grants Program to Support People Affected by Men..
09/06 ALKERMES : rsquo; Corporate Presentation to be Webcast at the Morgan Stanley Glo..
08/08 ALKERMES : Submits Supplemental New Drug Application to FDA for Two-Month Dosing..
07/28 ALKERMES PLC : Reports Second Quarter 2016 Financial Results
07/21 ALKERMES : to Host Conference Call to Discuss Second Quarter 2016 Financial Resu..
06/01 ALKERMES : rsquo; Corporate Presentation to Be Webcast at the Goldman Sachs 37th..
05/26 ALKERMES : Appoints Nancy Snyderman, M.D., to Board of Directors
05/25 ALKERMES : Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Dru..
05/24 ALKERMES : to Present Data on ALKS 5461 at Upcoming American Society of Clinical..
More news
Sector news : Biotechnology & Medical Research - NEC
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Biotechnology & Medical Research - NEC